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Severe skin diseases in children beyond topical therapy 
 
Editor: Wynnis L. Tom 





Many challenges face clinicians managing severe skin disease in children, including lack of 
high-quality evidence or licensed treatments, risk of therapy over prolonged periods and 
family factors that may influence treatment decisions. However, dermatologists and 
paediatricians looking after children with severe skin diseases need to be able to offer 
treatments for a range of different conditions. When managing conditions for which there is 
little high-quality published evidence, expert consensus or opinion from years of personal 
clinical experience becomes one of the most important sources of clinical guidance. This is 
recognized by editor Wynnis L. Tom, who quotes one author in the book’s introduction in 
saying that at the moment ‘our approaches are more art than science’ in the field of paediatric 
dermatology. 
As the title states, the emphasis is on managing paediatric patients with severe skin disease 
and goes beyond straightforward topical approaches. Rather than being a comprehensive 
paediatric dermatology textbook, the book focuses on systemic treatments for a number of 
severe skin conditions and groups of conditions, either the severe end of the spectrum of 
common skin diseases or rarer conditions. 
The text is divided into five sections, which are subdivided into chapters on one or a small 
number of related conditions: inflammatory skin diseases; immune-mediated and 










tumours. With the exception of one chapter, written by a UK-based dermatologist, the authors 
are all experts from the USA. Each chapter is clearly written and extensively referenced, and 
reads like a standalone review article. There is necessary repetition, for example, where 
systemic drugs are discussed in more than one section. For those not requiring the whole 
book, chapters can be purchased individually. 
Most of the chapters contain a brief clinical description, before a more in-depth discussion of 
therapeutic options. The text is illustrated with high-quality photographs and there are helpful 
summary tables in most chapters, including dosing schedules, monitoring and side-effects, 
which make the information more accessible and useful as a practical tool in the clinical 
setting. 
The book opens with the section on inflammatory skin diseases, which is subdivided into 
chapters on atopic dermatitis, psoriasis and pityriasis rubra pilaris, acne and hidradenitis 
suppurativa. 
In the sections on inflammatory skin disease, immune-mediated and autoimmune diseases, 
there are detailed descriptions of the various systemic options, accompanied by summary 
tables of dosing schedules, monitoring and side-effects. The chapters on eczema and psoriasis 
also discuss the evidence for and practical aspects of phototherapy. Evidence from paediatric 
studies is discussed where available, although there is also extrapolation from adult studies 
combined with the authors’ clinical experience. Published in 2014, discussion of the newest 
biologics for eczema, such as dupilumab, and psoriasis is not included; however, those 
available at the time of publication are discussed. 
There are clinical descriptions of acne vulgaris and related conditions, for example acne 
rosacea, periorificial dermatitis, severe subtypes such as acne conglobata and rarer syndromes 
such as SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis). This is followed by 
detailed discussions of antibiotics, isotretinoin and hormonal treatment. 
The chapter on autoimmune bullous diseases of childhood includes a useful table, which 
summarizes several immunobullous conditions with age of onset; triggers; clinical features, 
including distribution and involvement of mucous membranes; histopathology; 
immunofluorescence; antibody target; and prognosis. This is accompanied by an overview of 
the different therapeutic agents available, followed by detailed paragraphs describing the 
management of individual conditions. The subsequent chapter on connective tissue disease 










eosinophilic fasciitis, systemic sclerosis and juvenile dermatomyositis. There are boxes 
listing the clinical features of lupus and systemic sclerosis, and an overview table of the 
treatments used for paediatric connective tissue disease. 
Autoinflammatory syndromes are relatively recently described, and this chapter provides an 
interesting summary, including clinical features, genetic basis (where known) and treatment. 
As many patients also have an urticarial rash, the chapter concludes with how to distinguish 
autoinflammatory syndromes from chronic urticaria. 
The treatment of infantile haemangiomas has been revolutionized by the serendipitous 
discovery of propranolol. The chapter on the management of infantile haemangiomas 
contains comprehensive information on the mechanism of action and side-effects of 
propranolol and corticosteroids, with good practical advice on dosing and monitoring, and 
also information on vincristine and less common treatments. There are separate sections on 
PHACE (posterior fossa brain malformations, haemangioma, arterial lesions, cardiac 
abnormalities and eye abnormalities) and infantile haemangiomas affecting liver and airways. 
A multidisciplinary approach is emphasized by the authors of the chapter on complex 
vascular abnormalities, including a detailed discussion of imaging and haematological and 
thrombotic complications, with useful sections, including venous and lymphatic 
malformations, Klippel–Trenaunay syndrome, Proteus syndromes, arteriovenous 
malformations and Parkes Weber syndrome. The subsequent chapter on other vascular 
tumours includes discussion of Kaposiform haemangioendothelioma and tufted angioma, and 
the Kasabach–Merritt phenomenon ,with detailed paragraphs describing different treatment 
options and a summary table and algorithm. 
Increased knowledge of the underlying pathogenesis of genetic skin disease has led to 
targeted treatments for several rare genetic skin conditions. This interesting overview 
includes sections on the latest developments in our understanding and management, for 
example mammalian target of rapamycin inhibitors in tuberous sclerosis. A whole chapter is 
devoted to the multidisciplinary management of epidermolysis bullosa, with practical and 
experienced-based strategies for managing the associated multisystem pathology, 
complications and surveillance. Surveillance guidelines are helpfully tabulated and arranged 
by organ system. 
The final section of the book, which is on lymphoproliferative disorders, covers the spectrum 










varioliformis acuta) and FUMHD (febrile ulceronecrotic Mucha–Habermann disease) and 
cutaneous lymphoma, with clinical descriptions, treatment options and a discussion of the 
evidence. The book concludes with a useful chapter on paediatric mastocytosis, which 
includes a description of the clinical features, investigation and treatment options. These are 
tabulated with suggested dosing schedules and information on side-effects. 
Despite its small size, this book is a useful resource for those treating severe skin diseases in 
children. Many areas are covered in depth with a synthesis of the available evidence and 
experience-based management strategies derived from the authors’ clinical practice. As each 
chapter stands alone and can be read relatively quickly, with treatment schedules highlighted 
in summary tables, the book serves as a useful, practical resource for managing paediatric 
patients with severe skin disease. 
 
S. George 
Department of Dermatology, Brighton General Hospital, Brighton, UK 
Email: susannah@susannahgeorge.net 
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Table 1 
Socio-demographic and sexual behaviour characteristics of participants (last 12 months) 
 n % 
Country of Origin   
Spain 641 72.8 
Other 240 27.2 
Age   
16 to 34 years old 457 51.9 
35 to 49 years old 261 29.6 
50 years old or more 57 6.5 
Level Education   
Secondary school 56 6.4 
Vocational training 186 21.1 
Universitary 639 72.5 
Employment   
Employed 682 77.4 
Unemployed 47 5.3 
Student 145 16.5 
Retired 7 0.8 
Cohabitation situation   
Stable partner 196 22.2 
Alone 308 35 
Others (Family, shared apartment) 377 42.8 
Sexual orientation   
Gay/homosexual 775 85.7 
Bisexual 110 12.5 
Heterosexual 9 1 
Other 7 0.8 
Sexual orientation visibility   
All or almost all people 823 93.4 
None 58 6.6 
Sexual role   
Active / Insertive 244 27.7 
Versatile 433 49.1 
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Sexual partner   
Stable  73 8.3 
Occasional 357 40.5 
Both 316 35.9 
Occasional partners number   
1-2 81 9.2 
3-5 164 18.6 
6-10 188 21.3 
11-20 199 22.6 
21-50 124 14.1 
>50 106 12 
Sex under drug usea   
Never 654 74.2 
Sometime/habitually 227 25.8 
Chemsex participation   
Never  793 90 
Sometimes/usually 88 10 
PrEP useb   
Never 813 92.3 
Sometimes/usually 68 7.7 
Protection usec   
Always/almost always 310 35.2 
Never/almost never 571 64.8 
Previous diagnosis of STIs   
No 449 51 
Yes 432 49 
The denominators may vary depending on the answers given by the participants.  
STIs: Sexually Transmitted Infections. 
a Alcohol consumption is not included. 
b Among the participants who consumed Pre-Exposure Prophylaxis. 
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Table 2 
Characteristics of the participants according to Hepatitis A (HA) 
 n % 
Previous diagnosis of HAa   
No 387 89.6 
Yes 45 10.4 
HA Vaccine   
No 419 47.6 
Yes 462 52.4 
Recentlyb 138 15.6 
Second dose of HA vaccine   
No 176 38.1 
Yes 286 61.9 
HA vaccination initiative   
Own initiative 175 37.9 
Medical recommendation 287 62.1 
HA protection by PrEP 
consumptionc 
  
It doesn't protect me 47 69.1 
It does protect me 21 30.9 
The denominators may vary depending on the answers given by the participants.  
a Among participants diagnosed with sexually transmitted infections. 
b Hepatitis A vaccinations since 2017. 
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Table 3 
Unsafe sexual practices associated with the risk of Hepatitis A transmission according to 
sociodemographic characteristics and other contextual factors of  participants´ sexual 
relations. 
 Oro-anal Insertive-anal 
 Sometimes/habitually Sometimes/habitually 
 n % p* n % p* 
Country of Origin       
Spain 453 70.7 
0.512 
537 83.8 
0.650 Other 175 72.9 198 82.5 
Age       




35 to 49 years old 195 74.7 232 88.9 
50 years old or more 38 66.7 48 84.2 
Level Education       




Vocational training 135 72.6 159 85.5 
Universitary 457 71.5 533 83.4 
Employment       




Unemployed 32 68.1 37 78.7 
Student 97 66.9 110 75.9 
Retired 3 42.9 6 85.7 
Cohabitation situation       




Alone 230 74.7 266 86.4 
Others (Family, shared 
apartment) 264 70 306 81.2 
Sexual orientation       






Bisexuales 71 64.5 90 81.8 
Heterosexuales 4 44.4 4 44.4 
Sexual orientation visibility       
None 34 58.6 
0.040 
42 72.4 
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Sexual role       




Versatile 326 75.3 379 87.5 
Pasive / Receptive 120 58.8 135 66.2 
Sexual partner       




Occasional 282 79 316 88.5 
Both 262 84.4 298 94.3 
Occasional partners number       




3-5 106 64.6 131 79.9 
6-10 139 73.9 163 86.7 
11-20 148 74.4 168 84.4 
21-50 97 78.2 104 83.9 
>50 85 80.2 99 93.4 
Sex under drug use       
Never 443 67.7 
< 0.001 
526 80.4 
< 0.001 Sometime/habitually 185 81.5 209 92.1 
Chemsex participation       
Never  553 69.7 
0.003 
653 82.3 
0.015 Sometimes/usually 75 85.2 82 93.2 
PrEP use       
Never 572 70.4 
0.05 
676 83.1 
0.548 Sometimes/usually 56 82.4 59 86.8 
Protection use       
Always/almost always 178 57.4 
< 0.001 
225 72.6 
< 0.001 Never/almost never 450 78.8 510 89.3 
Previous diagnosis of STIs       
No 288 64.1 
< 0.001 
362 80.6 
0.028 Yes 340 78.7 373 86.3 
* p value: Pearson's Chi-square test and Fischer's exact test statistical significance p<0.05. 
PrEP: Human Immunodeficiency Virus Pre-Exposure Prophylaxis;  
STIs: Sexually transmitted infection. 
Chemsex: Intercourse intentionally under the consumption of psychoactive drugs in groups 
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Table 4 




 Sometimes/habitually Sometimes/habitually 
 OR (95%CI) p* OR (95%CI) p* 
Country of Origin       
Spain - - - 1   
Other - - - 1.81 (1.01-3.24) 0.046 
Employment       
Employed - - - 1   
Unemployed - - - 0.29 (0.11-0.73) 0.287 
Student - - - 1.05 (0.49-2.27) 1.051 
Retired - - - - - - 
Cohabitation situation       
Stable partner 1      
Alone 2 (1.13-3.55) 0.017 - - - 
Others (Family. shared 
apartment) 
1.58 (0.93-2.68) 0.093 - - - 
Sexual orientation       
Heterosexual - - - 1   
Gay/homosexual - - - 19.4 (1.99-
189.27) 
0.011 
Bisexual - - - 26.16 (2.24-
306.08) 
0.009 
Sexual rol       
Pasive/receptive 1   1   
Active/insertive 1.77 (1.02-3.06) 0.041 6.64 (2.89-
15.26) 
<0.001 
Versatile 1.8 (1.10-2.96) 0.02 3.98 (2.16-7.34) <0.001 
Sexual partner       
Stable 1   1   
Occasional 0.99 (0.51-1.93) 0.992 1.02 (0.45-2.34) 0.957 
Both 1.73 (0.90-3.53) 0.105 2.22 (0.91-5.42) 0.080 
Occasional partners 
number 










This article is protected by copyright. All rights reserved 
1-2 1   1   
3-5 1.14 (0.56-2.30) 0.724 1.42 (0.58-3.51) 0.445 
6-10 2.08 (1.01-4.32) 0.049 3.68 (1.39-9.79) 0.009 
11-20 2.12 (1.01-4.47) 0.048 3.06 (1.17-8) 0.023 
21-50 2.8 (1.21-6.46) 0.016 1.64 (0.62-4.39) 0.32 
>50 1.83 (0.80-4.19) 0.154 5.55 (1.37-
22.47) 
0.016 
Chemsex participation       
Never - - - 1   
Sometime/habitually - - - 5.15 (1.05-
25.15) 
0.043 
Protection use       
Always/almost always 1      
Never/almost never 3.28 (2-5.4) <0.001  - - 
Previous diagnosis of 
STIs 
      
No 1      
yes 1.74 (1.15-2.61) 0.008  - - 
OR: Odds Ratio; (IC95%): 95% confidence interval; p value: statistical significance of Wald's 
test p<0.05. 
PrEP: Human Immunodeficiency Virus Pre-Exposure Prophylaxis;  
STIs: Sexually transmitted infection. 
Chemsex: Intercourse intentionally under the consumption of psychoactive drugs. in groups 
and for long periods of time.  
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